AstraZeneca reports positive data from Phase III trial of Imfinzi

AstraZeneca has reported positive data from the EMERALD-1 Phase III trial of its human monoclonal antibody Imfinzi (durvalumab) plus TACE and bevacizumab, which demonstrated a progression-free survival (PFS) improvement in patients with unresectable hepatocellular carcinoma (HCC).